CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study.

Clicks: 304
ID: 58603
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Oropharyngeal mucositis occurs in virtually all patients with head and neck cancer receiving radiochemotherapy. The manipulation of the oral cavity microbiota represents an intriguing and challenging target.A total of 75 patients were enrolled to receive Lactobacillus brevis CD2 lozenges or oral care regimen with sodium bicarbonate mouthwashes. The primary endpoint was the incidence of grade 3 or 4 oropharyngeal mucositis during radiotherapy treatment.There was no statistical difference in the incidence of grade 3-4 oropharyngeal mucositis between the intervention and control groups (40.6% vs. 41.6% respectively, p=0.974). The incidence of pain, dysphagia, body weight loss and quality of life were not different between the experimental and standard arm.Our study was not able to demonstrate the efficacy of L. brevis CD2 lozenges in preventing radiation-induced mucositis in patients with head and neck cancer. Although modulating homeostasis of the salivary microbiota in the oral cavity seems attractive, it clearly needs further study.
Reference Key
de-sanctis2019anticancer Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors DE Sanctis, Vitaliana;Belgioia, Liliana;Cante, Domenico;LA Porta, Maria R;Caspiani, Orietta;Guarnaccia, Roberta;Argenone, Angela;Muto, Paolo;Musio, Daniela;DE Felice, Francesca;Maurizi, Francesca;Bunkhelia, Feisal;Ruo Redda, Maria Grazia;Reali, Alessia;Valeriani, Maurizio;Osti, Mattia F;Alterio, Daniela;Bacigalupo, Almalina;Russi, Elvio G;
Journal Anticancer research
Year 2019
DOI 10.21873/anticanres.13303
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.